Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Zanubrutinib: First Approval.

Literature DB >> 31933167

Zanubrutinib: First Approval.

Abstract

Zanubrutinib (Brukinsa®), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, based on overall response rate (ORR) seen in phase II and I/II clinical trials. This article summarizes the milestones in the development of zanubrutinib leading to this first approval for the treatment of MCL.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2020 PMID： 31933167 DOI： 10.1007/s40265-019-01252-4

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

6 in total

1. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors: Yi-Xin Zou; Hua-Yuan Zhu; Xiao-Tong Li; Yi Xia; Kou-Rong Miao; Si-Shu Zhao; Yu-Jie Wu; Li Wang; Wei Xu; Jian-Yong Li
Journal: Hematol Oncol Date: 2019-09-13 Impact factor: 5.271

2. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Authors: Thijs W H Flinsenberg; Charnelle C Tromedjo; Nan Hu; Ye Liu; Yin Guo; Kevin Y T Thia; Tahereh Noori; Xiaomin Song; Han X Aw Yeang; Daniela G Tantalo; Sasanka Handunnetti; John F Seymour; Andrew W Roberts; David Ritchie; Rachel Koldej; Paul J Neeson; Lai Wang; Joseph A Trapani; Constantine S Tam; Ilia Voskoboinik
Journal: Haematologica Date: 2020-01-31 Impact factor: 9.941

3. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Authors: Chiara Tarantelli; Lu Zhang; Elisabetta Curti; Eugenio Gaudio; Filippo Spriano; Valdemar Priebe; Luciano Cascione; Alberto J Arribas; Emanuele Zucca; Davide Rossi; Anastasios Stathis; Francesco Bertoni
Journal: Haematologica Date: 2019-01-24 Impact factor: 9.941

4. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.

Authors: Carrie J Li; Changying Jiang; Yang Liu; Taylor Bell; Wencai Ma; Yin Ye; Shengjian Huang; Hui Guo; Hui Zhang; Lai Wang; Jing Wang; Krystle Nomie; Liang Zhang; Michael Wang
Journal: Mol Cancer Ther Date: 2018-11-09 Impact factor: 6.261

5. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Authors: Constantine S Tam; Judith Trotman; Stephen Opat; Jan A Burger; Gavin Cull; David Gottlieb; Rosemary Harrup; Patrick B Johnston; Paula Marlton; Javier Munoz; John F Seymour; David Simpson; Alessandra Tedeschi; Rebecca Elstrom; Yiling Yu; Zhiyu Tang; Lynn Han; Jane Huang; William Novotny; Lai Wang; Andrew W Roberts
Journal: Blood Date: 2019-07-24 Impact factor: 22.113

Review 6. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors: Robert C Rickert
Journal: Nat Rev Immunol Date: 2013-08 Impact factor: 53.106

6 in total

18 in total

Review 1. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors: Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal: Signal Transduct Target Ther Date: 2021-05-31

Review 2. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.

Authors: Krista Isaac; Anthony R Mato
Journal: Cancer Manag Res Date: 2020-03-19 Impact factor: 3.989

Review 10. Current Treatment Options in CLL.

Authors: Moritz Bewarder; Stephan Stilgenbauer; Lorenz Thurner; Dominic Kaddu-Mulindwa
Journal: Cancers (Basel) Date: 2021-05-19 Impact factor: 6.639

Zanubrutinib: First Approval.

1. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

2. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

3. The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

4. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.

5. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Review 6. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Review 1. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Review 2. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.

Review 3. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.

Review 4. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.

Review 5. Current and future treatment strategies in chronic lymphocytic leukemia.

Review 6. Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review.

Review 7. Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.

Review 8. Repurposing anticancer drugs for the management of COVID-19.

Review 9. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.

Review 10. Current Treatment Options in CLL.